Diagnosis of mHSPC with histological or cytological evidence for adenocarcinoma of prostate
Metastatic disease by conventional or new generation imaging
* Physician decision to initiate treatment with Darolutamide+ADT was made as per investigator's routine treatment practice prior to enrollment in the study
* Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws).
You may not be if
Darolutamide treatment started more than 30 days prior to study enrollment
ADT treatment started more than 12 weeks before the start of treatment with darolutamide plus ADT
Hypersensitivity to darolutamide or any other excipient
Other prior systemic hormonal or anti-cancer treatment for mHSPC
Participation in an investigational program for prostate cancer with interventions outside of routine clinical practice
Clareo Health | How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany
